Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
종목 코드 FLGT
회사 이름Fulgent Genetics Inc
상장일Sep 28, 2016
CEOHsieh (Ming)
직원 수1313
유형Ordinary Share
회계 연도 종료Sep 28
주소4399 Santa Anita Ave
도시EL MONTE
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호91731
전화16263500537
웹사이트https://www.fulgentgenetics.com/
종목 코드 FLGT
상장일Sep 28, 2016
CEOHsieh (Ming)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음